[News Article: Baltimore Committee] Page: 1 of 6
[3] p. ; 28 cm.View a full description of this article.
- Highlighting
- Highlighting On/Off
- Color:
- Adjust Image
- Rotate Left
- Rotate Right
- Brightness, Contrast, etc. (Experimental)
- Cropping Tool
- Download Sizes
- Preview all sizes/dimensions or...
- Download Thumbnail
- Download Small
- Download Medium
- Download Large
- High Resolution Files
- IIIF Image JSON
- IIIF Image URL
- Accessibility
- View Extracted Text
Extracted Text
The following text was automatically extracted from the image on this page using optical character recognition software:
(AW) Conference Coverage (NCVDG): Baltimore Committee: Fill Gaps in HIV Vaccine Research
AIDSWEEKLY Plus, Monday, 19 May 1997 issue; Published by Charles Henderson, Publisher. Editorial & Publishing
Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409,
Birmingham, AL 35283-0409 /FAX: (205) 995-1588
by Daniel J. DeNoon, Senior Editor
Nobel Laureate David Baltimore has a plan for AIDS vaccine development: back to the basics.
Baltimore heads the National Institutes of Health AIDS Vaccine Research Committee, established in January 1997 to
coordinate the agency's efforts to develop an HIV vaccine. He spoke in a plenary address to the 9th Annual Meeting of the
National Cooperative Vaccine Development Groups for AIDS (NCVDG), held May 4-7, 1997, in Bethesda, Maryland.
Baltimore has his own ideas about the best approach to an AIDS vaccine. But he is committed to pursuing all approaches,
even those that now appear doomed.
"From the committee point of view it's 'let a thousand flowers bloom,"' he said. "I think this is the only reasonable approach."
Instead of dumping disappointing approaches, Baltimore urged researchers to go back to the drawing board and seek to
improve them.
For example, he said that there is "still a lot of opportunity" for peptide-based HIV vaccines. He urged that developers of
such vaccines try to maximize antigen presentation and to minimize their specificity.
While noting that live attenuated vaccines are the "most exciting today," he suggested that a killed-virus approach may be
more acceptable."A killed-virus vaccine is much easier to think about," Baltimore said. "I think we need to revivify this approach."
El I.
Upcoming Pages
Here’s what’s next.
Search Inside
This article can be searched. Note: Results may vary based on the legibility of text within the document.
Tools / Downloads
Get a copy of this page or view the extracted text.
Citing and Sharing
Basic information for referencing this web page. We also provide extended guidance on usage rights, references, copying or embedding.
Reference the current page of this Article.
DeNoon, Daniel J. [News Article: Baltimore Committee], article, May 19, 1997; Salem, Massachusetts. (https://texashistory.unt.edu/ark:/67531/metadc786220/m1/1/?q=%22Business%2C+Economics+and+Finance+-+Communications+-+Newspapers%22: accessed June 17, 2024), University of North Texas Libraries, The Portal to Texas History, https://texashistory.unt.edu; crediting UNT Libraries Special Collections.